Needham & Company
-
Tetralogic Pharmaceuticals (TLOG) Target Cut at Needham & Company; 'Buy' Maintained
-
Tetralogic Pharmaceuticals (TLOG) Sell-Off on Ovarian Cancer Data Overdone, Needham & Company Says
-
Needham & Company Comments on Tetralogic (TLOG) Following ASH Data; Sees Busy 2015, Compelling Valuation
-
Needham & Company Starts Tetralogic Pharmaceuticals (TLOG) at Buy
-
TetraLogic Announces Exercise of Over-Allotment Option
-
TetraLogic Announces Closing of Initial Public Offering of Common Stock
-
TetraLogic Pharmaceuticals (TLOG) IPO Trades Flat
-
TetraLogic (TLOG) Prices 7.15M Common IPO at $7/Share